Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics Announces Ability to Characterize Distinct Antigens between Cancers Using Monoclonal Antibody Technology
June 11th, 2008
ImmunoCellular Therapeutics, Ltd. (OTC: IMUC.OB) (IMUC), a biotechnology company, announced that preclinical in vitro data related to the characterization of the target associated with its lead monoclonal antibody (ICT-109) will be presented at ASCO. The abstract (#14023) titled "Differential glycan profile of CEACAM5 expressed by small cell lung carcinoma (SCLC) in comparison with colorectal carcinoma," demonstrated dramatic disparities between the sugar patterns of CEACAM5 on these two cancer types, potentially enabling the development of discerning therapeutics thereby allowing greater safety and efficacy. Furthermore, monoclonal antibody ICT-109 demonstrated the ability to bind to the...
Source: Vaccine Weekly (2008-06-11)
|
